The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
Open accessAbstract
Context: Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited. Objective: We aimed to describe baseline characteristics and outcomes of patients with malignant PHEO and PGL (PPGL) and to identify predictors of shorter survival. Design: Retrospective review of patients with malignant PPGL evaluated from 1960 to 2016. Setting: Referral center. Patients: The group comprised 272 patients. Main Outcome Measures: Baseline description, survival outcomes, and predictors of shorter survival were evaluated in patients with rapidly progressive (n = 29) and indolent disease (n = 188). Results: Malignant PPGL was diagnosed at a median age of 39 years (range, 7 to 83 years), with synchronous metastases in 96 (35%) patients. In 176 (65%) patients, metastases developed at a median of 5.5 years (range, 0.3 to 53.4 years) from the initial diagnosis. Median follow-up was 8.2 years (range, 0.01 to 54.1 years). Median overall and disease-specific survivals were 24.6 and 33.7 years, respectively. Shorter survival correlated with male sex (P = 0.014), older age at the time of primary tumor (P = 0.0011), synchronous metastases (P < 0.0001), larger primary tumor size (P = 0.0039), elevated dopamine (P = 0.0195), and not undergoing primary tumor resection (P < 0.0001). There was no difference in the type of primary tumor or presence of SDHB mutation. Conclusions: The clinical course of patients with malignant PPGL is remarkably variable. Rapid disease progression is associated with male sex, older age at diagnosis, synchronous metastases, larger tumor size, elevated dopamine, and not undergoing resection of primary tumor. An individualized approach to patients with metastatic PPGL is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathology and genetics of tumours of endocrine organs
DeLellis, R. A. (2004) · Cited by 1,122
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893
Genetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
Chen, H., Sippel, R. S., O'Dorisio, M. S., Vinik, A. I., Lloyd, R. V., & Pacak, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb4f0 · Cited by 593
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
Comino-Méndez, I., Gracia-Aznárez, F. J., Schiavi, F., Landa, I., Leandro-García, L. J., Letón, R., Honrado, E., Ramos-Medina, R., Caronia, D., Pita, G., et al. (2011) · Nature Genetics · doi:10.1038/ng.861 · Cited by 526
Clinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series.
Sutton, M. G. S. J., Sheps, S. G., & Lie, J. T. (1981) · PubMed · Cited by 453
Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0709 · Cited by 450
Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans
Goldstein, D. S., Eisenhofer, G., & Kopin, I. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049270 · Cited by 442
Ayala-Ramirez, M., Feng, L., Johnson, M. M., Ejaz, S., Habra, M. A., Rich, T., Busaidy, N., Cote, G. J., Perrier, N., Phan, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1946 · Cited by 428
National Cancer Data Base report on malignant paragangliomas of the head and neck
Lee, J. H., Barich, F., Karnell, L. H., Robinson, R. A., Zhen, W. K., Gantz, B. J., Hoffman, H. T., & American College of Surgeons Commission on Cancer and the American Cancer Society (2002) · Cancer · doi:10.1002/cncr.10252 · Cited by 427
Occurrence of Pheochromocytoma in Rochester, Minnesota, 1950 Through 1979
Beard, A. M., Sheps, S. G., Kurland, L. T., Carney, J. A., & Lie, J. T. (1983) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)18873-3 · Cited by 402
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
Castro-Vega, L. J., Buffet, A., De Cubas, A. A., Cascón, A., Menara, M., Khalifa, E., Amar, L., Azriel, S., Bourdeau, I., Chabre, O., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt639 · Cited by 397
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
Qin, Y., Yao, L., King, E. E., Buddavarapu, K., Lenci, R. E., Chocron, E. S., Lechleiter, J. D., Sass, M., Aronin, N., Schiavi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.533 · Cited by 379
Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K., Timmers, H. J., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.016 · Cited by 334
Brouwers, F. M., Eisenhofer, G., Tao, J. J., Kant, J. A., Adams, K. T., Linehan, W. M., & Pacak, K. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0423 · Cited by 316
Eisenhofer, G., Lenders, J. W., Timmers, H., Mannelli, M., Grebe, S. K., Hofbauer, L. C., Bornstein, S. R., Tiebel, O., Adams, K., Bratslavsky, G., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.153320 · Cited by 290
An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes
Gimenez-Roqueplo, A.-P., Dahia, P., & Robledo, M. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0031-1301302 · Cited by 288
Pheochromocytomas: can malignant potential be predicted?
John, H., Ziegler, W. H., Hauri, D., & Jaeger, P. (1999) · Urology · doi:10.1016/s0090-4295(98)00612-8 · Cited by 251
Prevalence of Clinically Unsuspected Pheochromocytoma. Review of a 50-Year Autopsy Series
Sutton, M. G. S. J., Sheps, S. G., & Lie, J. T. (1982) · Journal of Urology · doi:10.1016/s0022-5347(17)53807-0 · Cited by 237
Pheochromocytoma: New concepts and future trends
Bravo, E. L. (1991) · Kidney International · doi:10.1038/ki.1991.244 · Cited by 222
Clinical Spectrum and Outcome of Functional Extraadrenal Paraganglioma
O’Riordain, D. S., Young, W. F., Grant, C. S., Carney, J. A., & van Heerden, J. A. (1996) · World Journal of Surgery · doi:10.1007/s002689900139 · Cited by 201
Self-citationKing, K. S., Prodanov, T., Kantorovich, V., Fojo, T., Hewitt, J. K., Zacharin, M., Wesley, R., Lodish, M., Raygada, M., Gimenez-Roqueplo, A.-P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.6353 · Cited by 196
Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Jimenez, C., Rohren, E., Habra, M. A., Rich, T., Jimenez, P., Ayala-Ramirez, M., & Baudin, E. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0320-x · Cited by 178
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma
Lorenzo, F. R., Yang, C., Ng Tang Fui, M., Vankayalapati, H., Zhuang, Z., Huynh, T., Grossmann, M., Pacak, K., & Prchal, J. T. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0967-z · Cited by 171
Turková, H., Prodanov, T., Malý, M., Martucci, V. L., Adams, K. T., Widimsky, J., Jr., Chen, C. C., Ling, A. L., Kebebew, E., Stratakis, C. A., et al. (2015) · Endocrine Practice · doi:10.4158/ep15725.or · Cited by 147
Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location
Eisenhofer, G., Timmers, H. J. L. M., Lenders, J. W. M., Bornstein, S. R., Tiebel, O., Mannelli, M., King, K. S., Vocke, C. D., Linehan, W. M., Bratslavsky, G., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1588 · Cited by 124
Goffredo, P., Sosa, J. A., & Roman, S. A. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23297 · Cited by 99
Schovánek, J., Martucci, V. L., WESLEY, R. A., Fojo, T., Rivero, J. D., Huynh, T., Adams, K. T., Kebebew, E., Fryšák, Z., Stratakis, C. A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-523 · Cited by 83
Malignant head and neck paragangliomas: Treatment efficacy and prognostic indicators
Sethi, R. V., Sethi, R. K. V., Herr, M. W., & Deschler, D. G. (2013) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2013.03.010 · Cited by 57
Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas
Kim, K. Y., Kim, J. H., Hong, A. R., Seong, M., Lee, K. E., Kim, S., Kim, S. W., Shin, C. S., & Kim, S. Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168413 · Cited by 57
Malignant pheochromocytomas and paragangliomas: a diagnostic challenge
Gimm, O., DeMicco, C., Perren, A. A., Giammarile, F., Walz, M. K., & Brunaud, L. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0880-x · Cited by 51
Novel Hereditary Forms of Pheochromocytomas and Paragangliomas
Dahia, P. L. M. (2013) · Frontiers of hormone research · doi:10.1159/000345671 · Cited by 18
Cited by
Pheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
Self-citationNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Personalized Management of Pheochromocytoma and Paraganglioma
Nölting, S., Bechmann, N., Taieb, D., Beuschlein, F., Fassnacht, M., Kroiss, M., Eisenhofer, G., Grossman, A., & Pacak, K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab019 · Cited by 417
Lenders, J. W. M., Kerstens, M. N., Amar, L., Prejbisz, A., Robledo, M., Taieb, D., Pacak, K., Crona, J., Zelinka, T., Mannelli, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002438 · Cited by 413
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Metadata
- Authors
- Hamidi, O., Young, W. F., Iñiguez-Ariza, N. M., Kittah, N. E., Gruber, L., Bancos, C., Tamhane, S., & Bancos, I.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-06-12
- Volume
- 102
- Issue
- 9
- Pages
- 3296-3305
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2626337139
- Cited by
- 316
- References
- 33
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.